Methyltransferase‐Like Protein 14 Attenuates Mitochondrial Antiviral Signaling Protein Expression to Negatively Regulate Antiviral Immunity via N6‐methyladenosine Modification

• Main Authors: Fei Qin, Baoshan Cai, Jian Zhao, Lei Zhang, Yi Zheng, Bingyu Liu, Chengjiang Gao
• Format: Article
• Language: English
• Published: Wiley 2021-08-01
• Series: Advanced Science
• Subjects: antiviral immunity; N6‐methyladenosine modification; methyltransferase‐like protein 14; mitochondrial antiviral signaling protein; mRNA stability
• Online Access: https://doi.org/10.1002/advs.202100606

Abstract Mitochondrial antiviral signaling (MAVS) protein is the core signaling adaptor in the RNA signaling pathway. Thus, appropriate regulation of MAVS expression is essential for antiviral immunity against RNA virus infection. However, the regulation of MAVS expression at the mRNA level especially at the post transcriptional level is not well‐defined. Here, it is reported that the MAVS mRNA undergoes N6‐methyladenosine (m6A) modification through methyltransferase‐like protein 14 (METTL14), which leads to a fast turnover of MAVS mRNA. Knockdown or deficiency of METTL14 increases MAVS mRNA stability, and downstream phosphorylation of TBK1/IRF3 and interferon‐β production in response to RNA viruses. Compared to wild‐type mice, heterozygotes Mettl14+/− mice better tolerate RNA virus infection. The authors' findings unveil a novel mechanism to regulate the stability of MAVS transcripts post‐transcriptionally through m6A modification.